Sequence: HHHHHHHH
| Experiment Id | EXP001271 |
|---|---|
| Paper | Development of a multi-level pH-responsive lipid nanoplatform for efficient co-delivery of siRNA and |
| Peptide | SA-H8 |
| Delivery Success Class | yes |
| In Vivo Flag | yes |
| Uptake Confirmed | no |
| Label Confidence | medium |
| In Vitro Functional Effect | |
| Endosomal Escape Evidence | yes |
| Peptide Concentration | |
| Rna Concentration | 0.28 mg/kg |
| Mixing Ratio | SA-H8/siRNA N/P=5:1 |
| Formulation Format | N-LH/si (systemic) |
| Formulation Components | liposome core: DOPE/CHEMS/Chol; PEGylation: DSPE-PEG2000; SA-H8/siPLK-1 |
| Size Nm | 170.00 |
| Zeta Mv | |
| Model Scope | in_vivo |
| Model Type | in vivo |
| Cell Lines Or Primary Cells | |
| Animal Model | BALB/c nude mice with MCF-7 xenograft tumors |
| Administration Route | i.v. (tail vein) |
| Output Type | Tumor growth inhibition / PLK-1 silencing |
| Output Value | |
| Output Units | |
| Output Notes | Liposome group with siPLK-1 reduces PLK-1 expression in tumor and inhibits growth; less effective than Cyc-modified formulations. siRNA 0.28 mg/kg; DTX 0.86 mg/kg; dosing once every other day for 10 days (tumor suppression study) |
| Toxicity Notes | No significant body-weight loss reported |
| Curation Notes |